Carthera's ultrasound system earns EMA endorsement as an orphan medical device
The France-based company's SonoCloud system delivers ultrasound to temporarily open the blood-brain barrier. Activated ahead of drug administration, the skull implant is intended to allow therapeutic agents to better reach the brain.
Past research has shown that the blood-brain barrier, a natural filtration system of the brain, limits the penetration of more than 98% of drugs.
The endorsement means that Carthera will benefit from advice, including support around its clinical development strategy and clarification on the final steps before filing a European CE mark application for its SonoCloud system, from an EMA expert panel.
Intended for medical device manufacturers and notified bodies, the endorsement is part of an EU pilot programme to support early access pathways for innovative devices targeting rare diseases.
As part of the programme, the EMA has prioritised certain types of orphan medical devices such as those treating life-threatening medical conditions or those that could cause permanent impairment of a bodily function, and novel devices with potential major clinical benefits.
'This is a very important step for the company, since it creates a unique forum for dialogue with the expert panel prior to submitting the technical documentation for conformity assessment,' said Sandra Thiollière, director of regulatory affairs at Carthera.
'In parallel, we are continuing our early-stage contacts with our notified body to prepare for CE marking submission.'
Carthera is currently evaluating SonoCloud in improving the treatment of recurrent glioblastoma (rGBM).
In 2024, the Sorbonne University spinout shared results from a Phase I/II single-arm trial (NCT03744026) assessing the safety and efficacy of blood-brain barrier disruption with an implantable ultrasound system in rGBM patients receiving carboplatin.
In 12 patients who received carboplatin just before using the device, the one-year overall survival rate (OSR) was 58%, with a median OS of 14 months from surgery. The historical rate of survival for patients living with rGBM is around 9-11 months.
Carthera is currently recruiting patients for a pivotal trial of SonoCloud. The two-arm trial will enrol 560 patients and evaluate the system combined with carboplatin (CBDCA) versus standard of care, lomustine (CCNU) or temozolomide (TMZ), in patients undergoing planned resection for first recurrence glioblastoma.
"Carthera's ultrasound system earns EMA endorsement as an orphan medical device" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hackensack Meridian partners with CLEAR for patient identity
US-based comprehensive health network Hackensack Meridian Health has joined forces with CLEAR to enhance the patient experience through secure digital identity solutions. This collaboration aims to create a unified, interoperable identity across the Hackensack ecosystem. Integration of CLEAR's identity platform, CLEAR1, with the Epic healthcare solution is set to enhance the way patients engage with Hackensack's services. The forthcoming feature will allow patients to establish their MyChart accounts and reset passwords, and use a simple selfie for verification instead of the traditional methods. Hackensack Meridian Health CEO Robert Garrett said: 'Our partnership with CLEAR will make the check-in process as simple and secure as CLEAR's airport experience. This is a powerful example of how we leverage world-class technology to enhance the patient experience, improve access, and truly reimagine healthcare for our communities.' The initial phase of this technology rollout will focus on MyChart Account Creation and Password Reset. Subsequently, CLEAR's check-in technology is anticipated to launch at Hackensack University Medical Center's John Theurer Cancer Center. The facility is set to become the first in the US to adopt this solution. The technology, which will allow patients to check in for their appointment by clicking a photo at a kiosk, is also set to be implemented at the Hackensack Meridian Health and Wellness Center in Eatontown, with plans for a broader network expansion. Hackensack Meridian Health and CLEAR are exploring further opportunities to extend their collaboration. CLEAR CEO Caryn Seidman Becker said: 'CLEAR's mission is to make experiences safer and easier by connecting you to your secure identity.' Last year, Hackensack Meridian Health inaugurated a new health and wellness facility in Paramus, New Jersey, US. "Hackensack Meridian partners with CLEAR for patient identity" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Is Wall Street Bullish or Bearish on Thermo Fisher Scientific Stock?
With a market cap of $155.6 billion, Thermo Fisher Scientific Inc. (TMO) stands as a global leader in serving science, providing cutting-edge technologies, services, and solutions that drive research and enhance healthcare. The Waltham, Massachusetts-based company operates through four core segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Shares of TMO have underperformed the broader market, dropping 19% over the past year and 6% in 2025. In comparison, the broader S&P 500 Index ($SPX) has gained 16.4% over the past 52 weeks and 9.7% on a YTD basis. More News from Barchart Lyft Generates Huge FCF Margins - LYFT Stock Is Too Cheap Powell, Trump Talks and Other Can't Miss Items this Week 'My Kid Will Never Ever Be Smarter Than an AI': OpenAI's Sam Altman Warns Most Kids Won't Know a World Without AI Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Looking closer, the stock has also trailed behind the Health Care Select Sector SPDR Fund's (XLV) 10.8% decline over the past 52 weeks and a marginal fall year-to-date. Thermo Fisher released its Q2 2025 earnings on July 23, and its shares popped 9.1%. It reported revenue of $10.85 billion, a 3% year-over-year increase (with 2% organic growth). Adjusted EPS was $5.36, compared to $5.37 in the prior year, while adjusted operating income rose to $2.38 billion from $2.35 billion in the year-ago quarter. Thermo Fisher also highlighted the launch of next-generation instruments, including Orbitrap Astral Zoom, Orbitrap Excedion Pro, and the Krios 5 Cryo-TEM, as well as an expanded DynaDrive single-use bioreactor portfolio. For the fiscal year ending in December 2025, analysts expect TMO's adjusted EPS to grow 3% year-over-year to $22.52. The company's earnings surprise history is promising. It topped the consensus estimates in the last four quarters. Among the 26 analysts covering the stock, the consensus rating is a 'Strong Buy.' That's based on 18 'Strong Buy' ratings, three 'Moderate Buys,' and five 'Holds.' This configuration has been stable over the past months. On July 28, UBS analyst Dan Leonard downgraded Thermo Fisher to 'Neutral' from 'Buy,' cutting the price target to $460 from $500, citing concerns that persistent headwinds could weigh on life sciences R&D, which accounts for about half of the company's sales. UBS also forecast 2026 organic sales growth of 4%, 200 basis points below consensus, and reduced its longer-term outlook. TMO's mean price target of $553.60 implies a modest potential upside of 13.2% from the current price levels. Similarly, the Street-high price target of $650 indicates that the stock could soar by 32.9%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Chicago Tribune
2 hours ago
- Chicago Tribune
US pediatricians' new COVID-19 shot recommendations differ from CDC advice
NEW YORK — For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine recommendations. The group's new COVID-19 recommendations — released Tuesday — come amid a tumultuous year for public health, as vaccine skeptics have come into power in the new Trump administration and government guidance has become increasingly confusing. This isn't going to help, acknowledged Dr. James Campbell, vice chair of the AAP infectious diseases committee. 'It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them,' he added. The AAP is strongly recommending COVID-19 shots for children ages 6 months to 2 years. Shots also are advised for older children if parents want their kids vaccinated, the AAP said. That differs from guidance established under U.S. Health Secretary Robert F. Kennedy Jr., which doesn't recommend the shots for healthy children of any age but says kids may get the shots in consultation with physicians. Children ages 6 months to 2 years are at high risk for severe illness from COVID-19, and it was important that recommendations continue to emphasize the need for them to get vaccinated, said Campbell, a University of Maryland infectious diseases expert. Vaccinations also are recommended for older children who have chronic lung diseases or other conditions that put them at higher risk for severe disease, the AAP said. In a statement, Department of Health and Human Services spokesperson Andrew Nixon said 'the AAP is undermining national immunization policymaking with baseless political attacks.' He accused the group of putting commercial interests ahead of public health, noting that vaccine manufacturers have been donors to the AAP's Friends of Children Fund. The fund is currently paying for projects on a range of topics, including health equity and prevention of injuries and deaths from firearms. The 95-year-old Itasca, Illinois-based organization has issued vaccination recommendations for children since the 1930s. In 1995, it synced its advice with recommendations made by the federal government's Centers for Disease Control and Prevention. There have been a few small differences between AAP and CDC recommendations since then. For example, the AAP has advised that children get HPV vaccinations starting at age 9; the CDC says that's OK but has emphasized vaccinations at ages 11 and 12. But in 30 years, this is the first time the recommendations have differed 'in a significant or substantial way,' Campbell said. Until recently, the CDC — following recommendations by infectious disease experts — has been urging annual COVID-19 boosters for all Americans ages 6 months and older. But in May, U.S. Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. A few days later, the CDC issued language that healthy children may get the shots, but that there was no longer a 'should' recommendation. The idea that healthy older kids may be able to skip COVID-19 boosters has been brewing for some time among public health experts. As the COVID-19 pandemic has waned, experts have increasingly discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC expert panel in June was set to make recommendations about the fall shots. Among the options the panel was considering was whether suggest shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. But Kennedy bypassed the group, and also decided to dismiss the 17-member panel and appoint his own, smaller panel, that included vaccine skeptics. Kennedy also later excluded the AAP, the American Medical Association and other top medical organizations from working with the advisers to establish vaccination recommendations. Kennedy's new vaccine panel has yet to vote on COVID-19 shot recommendations. The panel did endorse continuing to recommend fall flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that people should only get flu vaccines that are packaged as single doses and do not contain the preservative thimerosal. The AAP said there is no evidence of harm from the preservative, and recommended doctors use any licensed flu vaccine product that's appropriate for the patient.
